Diaceutics was launched in 2005 by a trio of partners with significant experience
in developing and successfully commercializing both drugs and diagnostic tests,
with the purpose of providing an operational structure and process for pharmaceutical
drug development teams to successfully commercialize personalized medicine products.
Having accomplished that early goal, and with the continued rapid evolution of the
personalized medicine space and increasing demand from their clients, Diaceutics
began looking at ways to make their approach and process scalable. To accomplish
that goal, Diaceutics has built a catalog of personalized medicine specific software
applications that allow pharmaceutical companies to fully internalize the knowledge
and operational process developed by Diaceutics, and to begin to build a corporate
memory in the personalized medicine space.
|
|
|
|
|
Tiffany Olson, BSc MBA
Chairwoman of the Board
|
Peter Keeling, BA MA
Chief Executive Officer
|
Patrick Considine, PhD Chief Scientific Officer
|
|
|
|
|
|
Mollie Roth, JD
Chief Operating Officer
|
Tom Zietlow, PhD, MBA
President
|
Christof Koelsch, MD, PhD
Senior Vice President, Strategy & Innovation
|
|
|
|
|
|
Les Kondejewski, PhD
Director
|
Sanna Paakkonen, MSc
Director
|
Ryan Keeling, MEng
Senior Vice President, IT Solutions
|
|
|
|
|
|
Patrick Farnan, MEng
Software Architect
|
|
|